Annam Biosciences, LLC.

Annam's Technology (Patent Appl. No. PCT/US2013/056909)

We believe our novel small molecule multimeric structure (SMMS) drug conjugates have attributes that improve on native drug payload including enhancement of tumor specificity, reduction of adverse events, improvement in therapeutic efficacy and the ability to reach the tumor more effectively.



SMDCs: small molecule drug conjugates

siRNACs:  siRNA drug conjugates

ADCs: antibody drug conjugates